



**Making it easy** for your patients to get the testing they need at every step along the reproductive journey

From fertility and planning, through pregnancy, postpartum, and wellness



Fertility and planning



Prenatal genetics



Testing by trimester

## For patients considering pregnancy

### Diagnostic insights with enhanced clarity, so you may help your patients get pregnant faster

Rather than traditional testing methods, choose ReproSource, a Quest Diagnostics company for fertility testing, for actionable insights, easy-to-use tests, and easy-to-interpret reports.

### ReproSource gives you the insights you need to help address infertility earlier

With ReproSource, a Quest Diagnostics company for fertility testing, you can proactively offer advanced, affordable fertility testing to every couple at risk of infertility—testing that may help them get pregnant faster.

#### The Ovarian Assessment Report™ (OAR)

Using multiple reproductive hormones, patient age, and advanced mathematics, the OAR can better identify women at risk for low ovarian reserve.

#### @Home™ Collection for semen analysis test

With @Home™ Collection, male patients provide specimens in the comfort of their homes, avoiding potential issues of inconvenience, distance, or lack of privacy.



ReproSource is a national leader in specialty fertility diagnostic services. While ReproSource is a Quest Diagnostics affiliate, ReproSource and Quest are separate companies. As such, health plan access, test ordering, and billing processes may differ from those of Quest Diagnostics. Please note that ReproSource is not a Medicare/Medicaid provider. For more information, please contact ReproSource at 1.800.667.8893 or visit [ReproSource.com/Contact](https://ReproSource.com/Contact).

# ReproSource®

A Quest Diagnostics Company

### Beyond fertility testing: Our exceptional services make every day easier



**Specimen collection kits** to simplify collection and transport



**Insurance submissions and appeals**



**Patient-friendly reports**



**A vast network of experts** in fertility, hematology, immunology, endocrinology, and genetics are available for consultation

For more information about fertility testing with ReproSource, please visit or call us:

## Maximize clinical insights while minimizing uncertainty

### An important option for patients considering pregnancy

Genetic carrier screening provides a better understanding of the likelihood and potential impact of inherited genetic disorders. The American College of Obstetricians and Gynecologists (ACOG) recommends that all individuals, regardless of race or ethnicity, be offered screening for the same set of conditions.<sup>1</sup>

### Before pregnancy

This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

## Genetic carrier screening

Laboratory screening options	Quest test	Test code
Pan-ethnic carrier screen	<b>QHerit® Carrier Screening</b> An ideal panel for each patient: for a complete list of genes included in each QHerit panel, visit <a href="#">QHerit.com</a>	
	<b>445 diseases<sup>a</sup>, 445 genes</b> Expands upon the 421-disease panel and includes all 113 genes per ACMG tier 3 recommendations	Female: 13832 Male: 13831 <sup>a</sup>
	<b>421 diseases<sup>a</sup>, 421 genes</b>	Female: 12593 Male: 12594 <sup>a</sup>
	<b>150 diseases<sup>a</sup>, 150 genes</b>	Female: 39866 Male: 39987 <sup>a</sup>
	<b>84 diseases<sup>a</sup>, 85 genes</b>	Female: 39867 Male: 39988 <sup>a</sup>
	<b>22 diseases<sup>a</sup>, 24 genes</b> <b>The most common diseases</b> , including cystic fibrosis (CF), spinal muscular atrophy (SMA), fragile X, and Tay-Sachs	94372
Prenatal carrier screen	<b>Prenatal Carrier Panel<sup>b</sup></b> Includes CFvantage® (cystic fibrosis), spinal muscular atrophy (SMA), fragile X	93349
Cystic fibrosis	<b>CFvantage® Cystic Fibrosis Expanded Screen</b> 161 CF variants, including the 23 common variants aligned with ACOG guidelines <sup>2</sup>	92068
Fragile X	<b>XSense®, Fragile X with Reflex<sup>c</sup></b>	16313
Spinal muscular atrophy	<b>SMA Carrier Screen</b>	39445

<sup>a</sup> Panel components for males do not include specified X-linked diseases.

<sup>b</sup> Individual testing is available for partners of known carriers.

<sup>c</sup> Reflex testing may be performed at an additional charge.

While we offer comprehensive testing, some patients may have an interest in screening for a specific disorder, such as cystic fibrosis. For these patients, Quest Diagnostics offers single-gene screening.

Consultation is available on genetic test selection and results interpretation.

**Call 1.866.GENE.INFO (1.866.436.3463) Monday through Friday 8:30 AM to 8:00 PM EST**

Our QHerit Carrier Screening portfolio offers 5 clinically relevant and medically appropriate panels, screening for up to 445 diseases to provide greater insights that can help determine carrier risks of inherited genetic disease. See "Important information" on page 8.



Starts with a noninvasive, simple blood draw



Clinically relevant results



No Surprise patient program

## Screening is an important part of a healthy pregnancy

### Appropriate prenatal testing is a crucial part of caring for people who are expecting

This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

#### 1<sup>st</sup> trimester

Lab screening options	Quest test	Test code
<b>OB panel (tests can be ordered as a panel or individually)<sup>d</sup></b>	<b>Obstetric Panel</b>	<b>20210</b>
OB panel, individual components	<b>Complete blood count (CBC) (includes Differential and Platelets)</b>	6399
	<b>Antibody Screen, red blood cells (RBC) with Reflex to Identification, Titer, and Antigen Typing<sup>c</sup></b>	795
	<b>ABO Group and Rh Type</b>	7788
	<b>Rapid plasma reagin (RPR) (Diagnosis) with Reflex to Titer and Confirmatory Testing<sup>c</sup> (non-treponemal screening for syphilis)</b>	36126
	<b>Hepatitis B Surface Antigen with Reflex Confirmation<sup>c</sup></b>	498
	<b>Rubella Antibody (IgG), Immune Status</b>	802
<b>Additional OB Panel</b>	<b>Obstetric Panel with Fourth Generation HIV, Hepatitis C Antibody with Reflex</b>	<b>12075</b>
Additional OB Panel component	<b>Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR</b>	8472
<b>Additional OB Panel</b>	<b>Obstetric Panel with Fourth Generation HIV Individual components<sup>d</sup></b>	<b>93802</b>
Additional OB Panel component	<b>HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes<sup>c</sup></b>	91431
<b>Additional 1st trimester tests</b>		
Cervical cytology screening, if indicated <sup>e</sup>	<b>Image-Guided Pap with Age-Based Screening Protocols<sup>e</sup></b>	91384
	<b>Image-Guided Pap with Age-Based Screening with CT/NG<sup>e</sup></b>	91385
	<b>Image-Guided Pap with Age-Based Screening with CT/NG, <i>Trichomonas</i><sup>e</sup></b>	91386
	<b>Pap alone</b>	See note <sup>e</sup>
Urinalysis/Urine culture	<b>Urinalysis, Complete</b>	5463
	<b>Urinalysis, Complete, with Reflex to Culture<sup>c</sup></b>	3020
	<b>Culture, Urine, Routine</b>	395
TSH	<b>TSH, Pregnancy</b>	90896
	The American Association of Clinical Endocrinologists recommends TSH measurement in women of childbearing age before pregnancy or during the first trimester.	
Zika testing	<b>Zika Virus RNA, Qualitative, Real-Time RT-PCR</b>	93870
	<b>Zika Virus RNA, Qualitative, Real-Time RT-PCR Panel, Serum/Urine</b>	94221
	<b>Zika Virus RNA, Qualitative Real-Time RT-PCR, Serum/Urine and IgM Panel</b>	36758
Although rates of Zika virus infection have decreased in the United States, obstetricians/gynecologists and other healthcare providers should continue to assess their patients for potential exposure based on travel or sexual history and test symptomatic patients with possible exposure and pregnant women with ongoing exposure regardless of symptoms in accordance with the CDC recommendations. <sup>3</sup>		
Iron	<b>Iron, TIBC, and Ferritin Panel</b>	5616
	All pregnant women should be screened for anemia with a complete blood count in the first trimester and again at 24 0/7–28 6/7 weeks of gestation. <sup>4</sup>	

<sup>c</sup> Reflex testing may be performed at an additional charge.

<sup>d</sup> If Antibody Screen is positive, Antibody Identification, Titer, and Antigen Typing will be performed at an additional charge. If RPR screen is reactive, RPR Titer and FTA Confirmatory testing will be performed at an additional charge. When only a single test, Hepatitis B Surface Antigen, is ordered to diagnose Hepatitis B in a pregnant woman, additional tests such as liver enzymes should be ordered to confirm the diagnosis.

<sup>e</sup> The age-based offerings are based on ACOG recommendations and include image-guided Pap tests. Non-imaged Paps as well as conventional Paps are also available at Quest Diagnostics.

Lab screening options	Quest test	Test code
<b>Fetal aneuploidy 1st trimester testing</b>		
First Trimester Screen	<b>First Trimester Screen, hCG</b> The screen includes Pregnancy-associated Plasma Protein-A (PAPP-A), human chorionic gonadotropin (hCG), Nuchal Translucency (NT) test; and risk assessments for trisomy 21 and trisomy 18	16145
Noninvasive prenatal screening (NIPS)	QNatal® Advanced	92777
Maternal Serum Screen (Part 1)	<b>Stepwise, Part 1</b> The screen includes PAPP-A, hCG, NT test; and risk assessments for trisomy 21 and trisomy 18	16463
	<b>Serum Integrated Screen, Part 1</b> This screen includes PAPP-A; and risk assessments for trisomy 21 and trisomy 18 reported after Part 2	16165
	<b>Sequential Integrated Screen, Part 1</b> This screen includes PAPP-A, hCG, NT test; and risk assessments for trisomy 21 and trisomy 18	16131
	<b>Integrated Screen, Part 1</b> This screen includes PAPP-A, NT test; and risk assessments for trisomy 21 and trisomy 18 reported after Part 2	16148
Diagnostic fetal testing via chorionic villus sampling (CVS), if indicated	<b>Chromosome Analysis, Chorionic Villus Sample (CVS)</b>	14592
	<b>Chorionic Villus with Reflex to ClariSure® Oligo-SNP</b>	92808
	<b>FISH, Prenatal Screen</b>	14604
	<b>Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP</b>	90927
<small>Additional diagnostic testing, including fetal molecular tests, is available. Please refer to the Quest Diagnostics Test Directory or call 1.866.GENINFO (1.866.436.3463) for further information.</small>		
<b>Infectious disease 1st trimester tests</b>		
Tuberculosis (TB), if indicated <sup>f</sup>	<b>QuantiFERON®-TB Gold Plus, 1 Tube</b>	36970
	<b>QuantiFERON®-TB Gold Plus, 4 Tubes, Draw Site Incubated</b>	36971
	<b>T-SPOT®.TB</b>	37737
Chlamydia <sup>g</sup>	<b>Chlamydia trachomatis RNA, TMA, Urogenital</b>	11361
Gonorrhea, if indicated <sup>g</sup>	<b>Neisseria gonorrhoeae RNA, TMA, Urogenital</b>	11362
Chlamydia and gonorrhea (for all females ages 15-24 and those who are high risk)	<b>Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA, Urogenital</b>	11363
HIV testing	<b>HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes<sup>c</sup></b>	91431
Hepatitis C testing	<b>Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR<sup>c</sup></b>	8472
	<b>Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA<sup>c</sup></b>	94345
Syphilis	<b>Syphilis Antibody Cascading Reflex</b>	90349

<sup>c</sup> Reflex testing may be performed at an additional charge.

<sup>f</sup> Risk factors include known HIV infection; close contact with individuals known or suspected to have TB; medical risk factors such as diabetes, lupus, cancer, alcoholism, and drug addiction; birth in or emigration from countries with high prevalence; being medically underserved; homelessness, and living or working in long-term care facilities, such as correctional institutions, mental health institutions, and nursing homes.

<sup>g</sup> If positive, test-of-cure should be performed within 3-4 weeks post-treatment.

### QNatal® Advanced prenatal screening

QNatal Advanced is a noninvasive cfDNA prenatal screen that can help identify the most common fetal aneuploidies. In addition, QNatal Advanced can screen for sex chromosome abnormalities and certain microdeletions. See “Important information” on page 8.

Patient Navigators are our billing experts, available to provide out-of-pocket estimates for genetic tests such as QNatal, and information about financial assistance options for patients who qualify.

Call: **1.888.445.5011**

Email: [patientnavigators@questdiagnostics.com](mailto:patientnavigators@questdiagnostics.com)

### CDC recommends STI screening during pregnancy

According to the Centers for Disease Control and Prevention (CDC), pregnant patients should be tested for some STIs starting early in their pregnancy and repeating close to delivery, as needed. They also recommend open, honest conversations with pregnant patients and, when possible, their sex partners about symptoms and any high-risk sexual behaviors.<sup>5</sup>

### Making every day easier for your OBGYN office

Specially trained and dedicated Women’s Health service specialists are available for your support and service requests, alleviating some of the administrative burdens that can disrupt your day.

Visit [QuestDiagnostics.com/OBGYN](http://QuestDiagnostics.com/OBGYN) or call **1.844.QUESTOB (1.844.783.7862)**


## Maintaining prenatal care is essential, even as the due date approaches

### Second and third trimester screening can provide further insights to help ensure a healthy pregnancy and outcome

This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

## 2<sup>nd</sup> trimester

Lab screening options	Quest test	Test code
CBC	<b>CBC (includes Differential and Platelets)</b> This screen includes white blood count (WBC), RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (absolute and percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils)	6399
	<b>CBC (H/H, RBC, Indices, WBC, Plt)</b> This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count	1759
Gestational diabetes screening	<b>Glucose, Gestational Screen (50g), 135 Cutoff</b> (ACOG supported 1st step of 2-step gestational diabetes mellitus (GDM) evaluation)	8477
	<b>Glucose, Gestational Screen (50g), 140 Cutoff</b> (ACOG supported 1st step of 2-step GDM evaluation)	19833
	<b>Glucose Tolerance Test, Gestational, 4 Specimens (100g)</b> (ACOG supported 2nd step of 2-step GDM valuation)	6745
<b>Additional 2nd trimester testing</b>		
Quad Screen	<b>Quad Screen</b> This screen includes alpha-fetoprotein (AFP), unconjugated estriol (uE3), hCG, and dimeric inhibin A (DIA); and risk assessments for trisomy 21, trisomy 18, and open neural tube defects (ONTD)	30294
Maternal Serum Screen (Part 2)	<b>Serum Integrated Screen, Part 2</b> This screen includes AFP, uE3, hCG, DIA, and PAPP-A from Serum Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16167
	<b>Stepwise, Part 2</b> This screen includes AFP, uE3, hCG, DIA, PAPP-A and hCG from Stepwise, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16465
	<b>Sequential Integrated Screen, Part 2</b> This screen includes AFP, uE3, hCG, DIA, PAPP-A and hCG from Sequential Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16133
	<b>Integrated Screen, Part 2</b> This screen includes AFP, uE3, hCG, DIA, and PAPP-A, from Integrated Screen, Part 1; and risk assessments for trisomy 21, trisomy 18, and ONTD	16150
Maternal Serum Alpha-Fetoprotein (MSAFP)	<b>Maternal Serum AFP</b> This screen includes AFP and risk assessment for ONTD	5059
Diagnostic fetal testing via amniocentesis, if indicated	<b>Chromosome Analysis, Amniotic Fluid</b>	14590
	<b>Chromosome Analysis, Amniotic Fluid with Reflex to ClariSure® Oligo-SNP, Prenatal</b>	92704
	<b>Alpha-Fetoprotein, Amniotic Fluid and Reflex to AchE and Fetal Hgb</b>	232
	<b>Chromosomal Microarray, Prenatal, ClariSure® Oligo-SNP</b>	90927
	<b>FISH, Prenatal Screen</b> Additional diagnostic testing, including fetal molecular tests, is available. Please refer to the Quest Diagnostics Test Directory or call 1.866.GENE.INFO (1.866.436.3463) for further information.	14604



This resource provides a sampling of our comprehensive test menu. The determination of what testing is medically appropriate, including whether each of the individual components are appropriate, must be made by the ordering provider.

## 3<sup>rd</sup> trimester

Lab screening options	Quest test	Test code
CBC	<b>CBC (includes Differential and Platelets)</b> This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (absolute and percent neutrophils, lymphocytes, monocytes, eosinophils, and basophils)	6399
	<b>CBC (H/H, RBC, Indices, WBC, Plt)</b> This screen includes WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count	1759
D (Rh) antibody screen	<b>Antibody Screen, RBC with Reflex to Identification, Titer, and Antigen Typing<sup>c</sup></b>	795
Group B streptococcal disease	<b>Streptococcus Group B Culture</b>	5617
	<b>Streptococcus Group B with Susceptibility Culture</b>	15090
	<b>Streptococcus Group B DNA, PCR with Broth Enrichment</b>	91768
	<b>Streptococcus Group B DNA, PCR with Broth Enrichment and Reflex to Susceptibility<sup>c</sup></b>	91770
Chlamydia (if patient tested positive or is high-risk due to age or lifestyle)	<b>Chlamydia trachomatis RNA, TMA, Urogenital</b>	11361
Gonorrhea (if patient tested positive or is high-risk due to age or lifestyle)	<b>Neisseria gonorrhoeae RNA, TMA, Urogenital</b>	11362
Chlamydia and gonorrhea (if patient tested positive or is high-risk due to age or lifestyle)	<b>Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA, Urogenital</b>	11363
RPR (if patient tested positive or is high-risk due to age or lifestyle)	<b>RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing<sup>c</sup></b>	36126
HIV testing (if patient is high-risk due to lifestyle)	<b>HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes<sup>c</sup></b>	91431

### Retesting for STIs is important

Pregnant women with gonorrheal or chlamydial infections should be retested within 3 months after treatment.<sup>6</sup>



<sup>c</sup> Reflex testing may be performed at an additional charge.

# Advanced testing and insights that are more accessible and affordable

We've made testing easy with expansive health plan coverage, flexible financial options, easy-to-use online tools, and specialized support.



## Make it easy for patients to get the testing they need

- **In-network for >90% of covered lives<sup>h</sup>** and preferred lab network status with major health plans
- **Financial assistance program** helps qualified patients receive testing at no cost or at a reduced patient price
- **MyQuest<sup>®</sup>** helps patients schedule appointments and securely access results



## Get relevant answers and specific guidance

- **Specialty Testing Services** team provides prior authorization and patient billing support for genetic testing. Visit [QuestDiagnostics.com/STS](https://www.questdiagnostics.com/STS)
- **For OBGYNs**, exclusive access to dedicated Women's Health service specialists. Visit [QuestDiagnostics.com/OBGYN](https://www.questdiagnostics.com/OBGYN) or call **1.844.QUESTOB (1.844.783.7862)**



## Simplified processes

- **Quantum<sup>®</sup> solutions** make it easy to order tests and get results
- Interfaces with **hundreds of EHR systems**

<sup>h</sup>This is directional data. It is based on 2020 HealthLeaders membership data of private third-party payers at the Managed Care Organization (MCO) level, as well as Quest internal data. Information is believed to be accurate as of January 1, 2020; however, it is subject to change.



For more information, visit [QuestWomensHealth.com](https://www.questwomenshealth.com)



### Important information

\* QHerit<sup>®</sup>, QHerit Plus, QHerit Extended, QHerit 421, QHerit 381, QHerit 445, and QHerit 400 are carrier "screening" tests, and they screen for variations in genes linked to certain health disorders that can be passed from parents to children. QHerit screens 24 genes; QHerit Plus screens 85 genes; QHerit Extended screens 150 genes; QHerit 421 screens 421 genes; QHerit 381 screens 381 genes; QHerit 445 screens 445 genes; and QHerit 400 screens 400 genes. For a full list of genes for which each panel in the QHerit family screens, visit [QHerit.com](https://www.questdiagnostics.com). If the results from any panel in the QHerit family suggest a patient may be a carrier of a gene variation that can cause a health disorder in offspring, it is recommended that the reproductive partner be offered genetic screening and genetic counseling be provided for both partners. Pregnancy management decisions should not be based on the results of these screening tests alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic variation and may be lower for rare conditions. Patients should discuss with their provider reproductive implications and the need for further testing based on screening results. Each panel in the QHerit family is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA) and, as such, has not been reviewed by the FDA.

\*\* QNatal<sup>®</sup> Advanced is a cell-free DNA test that screens for increased risk of certain fetal chromosomal abnormalities that may cause birth defects, including Trisomy 21 (Down Syndrome), Trisomy 18, Trisomy 13, and certain sex chromosome abnormalities (ie, 45,X; 47,XXY; 47,XXX; and 47,XY). In addition, if selected as an option, QNatal Advanced can screen for certain microdeletions (ie, 22q, 5p, 1p36, 15q, 11q, 8q, and 4p) that may cause birth defects, and/or for fetal sex. This test does not assess the risk of fetal anomalies such as neural tube defects or ventral wall defects. QNatal Advanced is not recommended before 10 weeks gestation due to a significantly increased risk of a failed result. QNatal Advanced is a laboratory-developed test that has been developed and validated pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA), and as such it has not been reviewed by FDA.

QNatal is a "screening" test, not a diagnostic test, and therefore all positive/increased risk results should be followed by genetic counseling and further diagnostic testing and procedures, when clinically indicated. Pregnancy management decisions should not be based on the results of a cfDNA test alone. As with any test, there may be false positives or false negatives. The positive predictive value of the screening test varies by genetic marker and may be lower for rare conditions. Performance data for QNatal Advanced may be obtained by contacting Quest Diagnostics at 1.866.GENE.INFO (1.866.436.3463).

### References

1. ACOG. Committee opinion no. 690: carrier screening in the age of genomic medicine. *Obstet Gynecol.* 2017;129(3):595-596. doi:10.1097/AOG.0000000000001947
2. American College of Obstetricians and Gynecologists Committee on Genetics. Carrier screening for genetic conditions: Committee opinion number 691. March 2017 (Reaffirmed 2020). Accessed January 24, 2023. <https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions.pdf>
3. ACOG. Committee opinion no. 784: management of patients in the context of Zika virus. *Obstet Gynecol.* 2019;134(3):655-657. doi:10.1097/AOG.00000000000003400
4. ACOG Committee on Practice Bulletins, Anemia in pregnancy: ACOG practice bulletin number 233. *Obstet Gynecol.* 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477
5. CDC. STDs during pregnancy. Updated April 11, 2023. Accessed May 15, 2023. <https://www.cdc.gov/std/pregnancy/stdfact-pregnancy-detailed.htm>
6. CDC. Sexually transmitted infections treatment guidelines, 2021 - pregnant women. Updated July 22, 2021. Accessed May 15, 2023. <https://www.cdc.gov/std/treatment-guidelines/pregnant.htm>

Image content features models and is intended for illustrative purposes only.

Test codes may vary by location. Please contact your local laboratory for more information.

### QuestDiagnostics.com

Quest<sup>®</sup>, Quest Diagnostics<sup>®</sup>, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—<sup>®</sup> and <sup>™</sup>—are the property of their respective owners. © 2023-2024 Quest Diagnostics Incorporated. All rights reserved. SB12943 9/2024